Elekta, a global leader in brachytherapy solutions, has acquired iCAD, Inc.’s Xoft business, including the innovative Xoft Axxent Electronic Brachytherapy (eBx) System. This technology, utilizing a miniaturized X-ray source, offers precise cancer treatment with minimal shielding. Elekta aims to expand brachytherapy adoption, reduce operational costs for clinics, and provide tailored radiation therapy options. The transaction is set to conclude in the second quarter of Elekta’s fiscal year 2023/24, strengthening Elekta’s position in personalized and precise cancer care.
Elekta, a global leader in brachytherapy solutions, has recently expanded its portfolio by acquiring the Xoft business from iCAD, Inc. This acquisition, structured as an asset purchase, includes the innovative Xoft Axxent Electronic Brachytherapy (eBx) System and involves the transition of staff members. This expansion allows Elekta to introduce electronic brachytherapy technologies, enhancing its capacity to offer a broader spectrum of cancer treatment methods.
The Xoft system distinguishes itself by utilizing a miniaturized X-ray source for radiation, replacing traditional radioactive isotopes. This technology is adaptable across various clinical environments due to its minimal shielding requirements. Presently, it’s primarily utilized in the intraoperative treatment of breast cancer, non-melanoma skin cancer, and gynecological cancers, with plans to extend its applications to other clinical areas.
John Lapré, President of Brachy and Neuro Solutions at Elekta emphasized the significance of incorporating Xoft’s technology. He highlighted the anticipated growth in brachytherapy adoption and the consequent increase in treatment accessibility for eligible patients. This acquisition aims to deliver diverse, clinic-specific radiation therapy options, aiming to lower operational costs by reducing shielding necessities and logistical hurdles associated with handling radioactive materials.
The Xoft System, already implemented in over 100 systems, now joins Elekta’s extensive product range, including the Elekta Flexitron afterloaders, totaling 1,900 units worldwide. With Elekta’s global presence in over 120 countries, the integration of Xoft technology is set to extend its reach, providing more patients with access to targeted, precise radiation therapy.
The deal is set to finalize in the second quarter of Elekta’s 2023/24 fiscal year. The Xoft System is both FDA-cleared and CE-marked, affirming its approval for cancer treatment in any body part. This system leverages a compact X-ray source to administer concentrated radiation directly to tumor sites, exemplifying precision in cancer treatment.
